COMMUNIQUÉS West-GlobeNewswire

Apella Raises $80 Million to Transform the Hospital with Ambient AI and Computer Vision
08/01/2026
The company has supported 500,000 surgical cases to date; strategic investment will fuel expansion to new health systems SAN FRANCISCO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Apella , a health technology company, today [...]
Recovery First Treatment Center Names Executive Director With 25 Years of Behavioral Healthcare Leadership
08/01/2026
HOLLYWOOD, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Recovery First Treatment Center, a Florida drug treatment center , has named Scott Frankel as Executive Director. Frankel is a healthcare executive with over 25 years [...]
CHINA SXT PHARMACEUTICALS, INC. ANNOUNCES STRATEGIC AI INSIGHTS INITIATIVE TO OPTIMIZE TRADITIONAL CHINESE MEDICINE PORTFOLIO, ENHANCE MARKET ANALYSIS AND EXPLORE AI-SUPPORTED CLINIC DEPLOYMENT
08/01/2026
TAIZHOU, China, Jan. 08, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, manufacturing, [...]
Akari Therapeutics to Present at the 2026 Biotech Showcase
08/01/2026
In-person presentation on Tuesday, January 13 th at 9:30 AM PT As part of the presentation, Mr. Gaslightwala will provide an overview of Akari’s ADC platform, strategic priorities and key milestones for 2026 TAMPA, Fla [...]
Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock
08/01/2026
WESTLAKE VILLAGE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux”) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced the pricing of an underwritten public offering [...]
Synfini Opens Cloud Access to its Agile AI Foundry to Accelerate Discovery of Better Molecules
08/01/2026
Democratized access to validated, reproducible, multistep & multiscale chemistry for modern molecular discovery MENLO PARK, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Synfini , Inc., provider of the industry’s most [...]
Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor
08/01/2026
Founding CEO Barbara Weber, M.D. to become executive chair of the board of directors Malte Peters, M.D., current board member, appointed President and Chief Executive Officer, effective immediately – BOSTON, Jan. 08, [...]
PacBio and UC Davis Researchers Introduce CiFi, a New Long-Read 3C Method That Enables Chromosome-Scale Assemblies from a Single SMRT Cell
08/01/2026
Community-developed approach combines multi-contact 3C with HiFi sequencing to deliver haplotype-resolved assemblies from minimal input material MENLO PARK, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB [...]
Lynn Stockwell and Bright Green Corporation File $3 Billion Lawsuit Against Rodey Law Firm and Attorneys’ Liability Assurance Society (ALAS) for Legal Malpractice and Bad Faith
08/01/2026
Court Found No Wrongdoing by Lynn Stockwell; Judgment Imposed Joint and Several Liability Due to Counsel’s Failure Cibola County, New Mexico, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Bright Green Corporation (OTC: BGXXQ) and [...]
Omada Health’s GLP-1 Behavior Change Companion Programs Help Drive Lasting, Long-Term Weight Loss
08/01/2026
New analysis adds to existing evidence that Omada’s program paired with GLP-1 medications leads to greater weight loss and persistence than reported in real world evidence SAN FRANCISCO, Jan. 08, 2026 (GLOBE NEWSWIRE [...]
Marius Pharmaceuticals to Initiate Study Evaluating KYZATREX® (testosterone undecanoate) CIII Capsules in Men Ages 65–80
08/01/2026
RALEIGH, N.C., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, Inc. today announced the company will initiate a new post-marketing clinical study for potential label expansion evaluating KYZATREX ® ( [...]
Polyrizon Completes Branding Process for PL-14 Allergy Blocker with Brand Name NASARIX™
08/01/2026
As part of the branding process, Polyrizon conducted comprehensive trademark screening across the U.S. and European markets Raanana, Israel, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. Polyrizon Ltd. (Nasdaq: PLRZ [...]
Biofrontera Inc. Announces Data Base Locks for Two Clinical Studies Supporting Key Data and Regulatory Milestones
08/01/2026
Database locks for studies on actinic keratosis (AK) and acne vulgaris achieved on January 5, 2026 Data generated will support key regulatory milestones for Ameluz PDT in both indications AK and acne are the two most [...]
Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T
08/01/2026
1H 2026 Catalyst Stack Anticipated to Validate Scalable, Off-the-Shelf CAR T in Oncology and Autoimmune Disease Interim Futility Analysis of MRD Clearance from the Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene [...]
Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates
08/01/2026
Received $35.8 million in gross proceeds from Series B warrant exercises, including full exercise by Coastlands Capital, Frazier Life Sciences and Gilead Sciences, Inc., and extended anticipated cash runway into second [...]
Ardelyx Reports Preliminary 2025 Revenue and Provides 2026 Strategic Outlook
08/01/2026
Company achieved significant commercial progress in 2025, generating approximately $378 million in product revenue 1 IBSRELA achieved $274 million in revenue in 2025, representing 73% growth vs. 2024 1 IBSRELA expected [...]
ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004
08/01/2026
- First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and physician’s choice of chemotherapy in HER2-positive metastatic breast cancer; interim analysis anticipated [...]
RenovoRx To Announce Promising New Clinical Data Using its TAMP™ Therapy Platform in an Abstract to be Presented at ASCO GI 2026
08/01/2026
New Pharmacokinetic (PK) and Pharmacodynamic Data from Sub-Study in Phase III Trial Strengthens Scientific Basis for RenovoRx’s TAMP Therapy Platform as a Targeted Drug-Delivery Approach Data Shows a PK Profile that May [...]
Tris Pharma Announces Acceptance of New Publication Highlighting Promise of Dual NOP-MOP (dual-NMR) Agonists for the Treatment of Moderate-to-Severe Pain
08/01/2026
– Preferential MOP agonists such as oxycodone are often required for effective management of moderate to severe pain but come with significant risks of addiction and overdose – – With Dual NMR agonists, NOP and MOP [...]

Pages